November 03, 2009 07:00 AM US Eastern Timezone Arrowhead Research Corporation’s (NASDAQ: ARWR) President and Chief Executive Officer today issued the following letter to the Company’s shareholders: PASADENA, Calif.--... [read full story]
|
RELATED
|
|
Arrowhead Research Corporation (NASDAQ:ARWR) today announced that its majority owned subsidiary, Calando Pharmaceuticals, Inc., has appointed Mostafa Analoui, Ph.D., and Bruce D. Given, MD, to its Board of Directors.
“We’re delighted to welcome Bruce and Mostafa to the Calando Board of Directors,” said Dr. Christopher Anzalone, Arrowhead's President and Chief Executive Officer. Dr. Given is a healthcare products consultant and is the...
Dr. Given is a healthcare products consultant and is the Principal of Bruce Given Consulting. Prior to the establishment of his consulting practice, Dr. Given was President and Chief Executive Officer of Encysive...
is a healthcare products consultant and is the Principal of Bruce Given Consulting. Prior to the establishment of his consulting practice, Dr. Given was President and Chief Executive Officer of Encysive Pharmaceuticals Inc.,...
Arrowhead Research Corporation (NASDAQ:ARWR) today announced that its majority owned subsidiary, Calando Pharmaceuticals, Inc., has appointed Mostafa Analoui, Ph.D., and Bruce D. Given, MD, to its Board read more
Arrowhead Research Corporation (NASDAQ:ARWR) today announced that its majority owned subsidiary, Calando Pharmaceuticals, Inc., has appointed Mostafa Analoui, Ph.D., and Bruce D. Given, MD, to its Board of Directors.
Arrowhead Research Corporation (NASDAQ:ARWR) today announced that its majority owned subsidiary, Calando Pharmaceuticals, Inc., has appointed Mostafa Analoui, Ph.D., and Bruce D. Given, MD, to its Board of Directors. “We’re...
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Research Corporation’s (NASDAQ: ARWR) President and Chief Executive Officer today issued the following letter to the Company’s shareholders: Dear Arrowhead Shareholders: It has now...
Arrowhead Research Corporation’s (NASDAQ: ARWR) President and Chief Executive Officer today issued the following letter to the Company’s shareholders: Dear Arrowhead Shareholders: It has now been almost three months since our...
Dear Arrowhead Shareholders: It has now been almost three months since our last earnings call, and I wanted to provide our shareholders with a broad strategic and operational update. Since then, we have made considerable...
Investing & Markets, Television Sets, Consumer Electronics, Information & Communication Technology, Scientific Discoveries, General Management Issues, Health Care, Finance, Banking & Insurance, Ambulatory Health Care, Senior Management, Manufacturing, Board of Directors, Financial Markets, LCD TV Sets, Corporate Performance, Medical Research, Stock Markets, Investing, Earnings Surprises, Earnings Estimates, CEO, Corporate Earnings, Calando Pharmaceuticals, Arrowhead Research Corporation, United States of America, California, Shizuoka Prefecture, Japan, Southern California, North America, Ito, Pasadena (California)
